--- title: "Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 2.6% - Here's Why" description: "Phathom Pharmaceuticals (NASDAQ:PHAT) shares fell 2.6% to $12.96, with trading volume down 44% from average levels. Analysts have mixed ratings, with one Strong Buy, four Buy, one Hold, and one Sell. " type: "news" locale: "en" url: "https://longbridge.com/en/news/261706165.md" published_at: "2025-10-18T06:28:07.000Z" --- # Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 2.6% - Here's Why > Phathom Pharmaceuticals (NASDAQ:PHAT) shares fell 2.6% to $12.96, with trading volume down 44% from average levels. Analysts have mixed ratings, with one Strong Buy, four Buy, one Hold, and one Sell. The stock has a Moderate Buy rating and a consensus target price of $17.50. Institutional investors own 99.01% of the company, which focuses on treatments for gastrointestinal diseases. Despite the recent decline, some analysts suggest better investment opportunities exist outside of Phathom Pharmaceuticals. Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report)'s share price fell 2.6% during trading on Friday . The stock traded as low as $12.56 and last traded at $12.96. 778,019 shares were traded during mid-day trading, a decline of 44% from the average session volume of 1,396,707 shares. The stock had previously closed at $13.31. ## Analysts Set New Price Targets Several brokerages have recently commented on PHAT. Wall Street Zen raised Phathom Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Phathom Pharmaceuticals in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $17.50. **View Our Latest Stock Analysis on Phathom Pharmaceuticals** ## Phathom Pharmaceuticals Stock Performance The company has a market cap of $919.38 million, a price-to-earnings ratio of -2.74 and a beta of 0.43. The business has a 50-day simple moving average of $11.70 and a 200-day simple moving average of $8.31. ## Institutional Investors Weigh In On Phathom Pharmaceuticals Hedge funds have recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. acquired a new stake in Phathom Pharmaceuticals in the 1st quarter valued at about $3,738,000. GAMMA Investing LLC raised its position in Phathom Pharmaceuticals by 797.2% in the 1st quarter. GAMMA Investing LLC now owns 4,558 shares of the company's stock valued at $29,000 after purchasing an additional 4,050 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Phathom Pharmaceuticals in the 1st quarter valued at about $262,000. US Bancorp DE increased its holdings in shares of Phathom Pharmaceuticals by 248.1% in the 1st quarter. US Bancorp DE now owns 23,763 shares of the company's stock valued at $149,000 after acquiring an additional 16,937 shares during the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of Phathom Pharmaceuticals by 47.6% in the 1st quarter. Wellington Management Group LLP now owns 200,690 shares of the company's stock valued at $1,258,000 after acquiring an additional 64,695 shares during the last quarter. Institutional investors and hedge funds own 99.01% of the company's stock. ## About Phathom Pharmaceuticals (Get Free Report) Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. ## See Also - Five stocks we like better than Phathom Pharmaceuticals - 3 Warren Buffett Stocks to Buy Now - This AI Chip Giant Could Be the Market’s Next Big Winner - What Are the U.K. Market Holidays? How to Invest and Trade - Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock - Are Penny Stocks a Good Fit for Your Portfolio? - Institutions Are Fueling CrowdStrike’s Next Leg Higher *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Phathom Pharmaceuticals Right Now? Before you consider Phathom Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list. While Phathom Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [PHAT.US - Phathom Pharmaceuticals](https://longbridge.com/en/quote/PHAT.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Phathom Pharmaceuticals 轉向專注於胃腸道領域，目標是在 2026 年下半年實現盈利，CEO 在 Guggenheim 峯會上表示 | Phathom Pharmaceuticals 首席執行官 Steven Basta 在古根海姆峯會上宣佈，公司正專注於胃腸病學，目標是在 2026 年下半年實現盈利。該公司的產品 VOQUEZNA 於 2023 年 11 月推出，首年收入 | [Link](https://longbridge.com/en/news/275987764.md) | | Phathom Pharmaceuticals（PHAT）啓動 1.3 億美元的公開募股 | Phathom Pharmaceuticals (PHAT) 已啓動公開募股，計劃籌集約 1.3 億美元，涉及 688 萬股，每股定價為 16.00 美元。這些資金將用於支持一般企業用途，包括研發。該公司面臨重大財務挑戰，負利潤率和 Alt | [Link](https://longbridge.com/en/news/271899916.md) | | 英偉達股價下跌，但有兩個積極的理由 | 英偉達的股票在最近幾個月保持平穩，但對於耐心的投資者來説，有一些好跡象 | [Link](https://longbridge.com/en/news/276138545.md) | | Phathom Pharmaceuticals 在宣佈計劃進行股權融資後股價下跌 | Phathom Pharmaceuticals 的股價下跌 10.1%，至 16.25 美元，此前該公司宣佈計劃進行一項涉及股票和預先融資認股權證的股權融資，交易規模未披露。該公司旨在將所得款項用於一般企業用途，包括營運資金和研發。預計第四 | [Link](https://longbridge.com/en/news/271842495.md) | | Phathom Pharmaceuticals 公佈三期臨牀試驗結果 | Phathom Pharmaceuticals（PHAT）宣佈在《美國胃腸病學雜誌》上發佈了 VOQUEZNA®（vonoprazan）第三階段臨牀試驗結果，顯示非侵蝕性胃食管反流病（NERD）患者的無燒心夜數顯著改善。該股票評級為持有，目 | [Link](https://longbridge.com/en/news/262871423.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.